Analysis of the detailed Chinese instructions for tepotinib

1. Basic information about drugs

Chinese name: Tepotinib

English name:Tepotinib

Product name:TEPMETKO

Dosage form and specifications: Oral tablets, the usual dosage is225mg/tablet, 450mg per day (i.e. 2 tablets)

Target population: Non-small cell lung cancer (NSCLC)

Target:MET exon 14 skipping mutation (METex14 skipping mutation)

2. Analysis of indications

Tepotinib is the first targeted drug approved by the FDA for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. This type of mutation accounts for approximately 3% to 4% of all NSCLC patients, and often responds poorly to traditional chemotherapy or first-generation EGFR-TKI treatment, with limited treatment options. Tepotinib's targeting mechanism can effectively inhibit the abnormal MET signaling pathway and block the proliferation and metastasis of tumor cells. The drug is particularly useful in patients who are not candidates for surgical resection, are intolerant to standard treatments, or have failed previous treatments.

3. Usage and dosage recommendations

The recommended dose is 450 mg once a day, with food, and continued until disease progression or unacceptable adverse reactions occur. In clinical use, it is not recommended to reduce the dosage or discontinue the drug without authorization. The dosage needs to be adjusted according to the degree of adverse reactions under the guidance of a specialist. For example, for drug-related toxicity of grade 3 or higher, treatment may be suspended or the dosage may be reduced to 225 mg daily.

4. Efficacy and safety evaluation

The efficacy of Tepotinib has been verified byVISION study. In this international multi-center clinical trial, the objective response rate (ORR) reached 43% and the median duration of response (DOR) exceeded 11 months, providing a clear survival advantage for patients carrying METex14 mutations. In terms of safety, common adverse reactions include edema, fatigue, nausea, diarrhea and hypoalbuminemia. Most of them are grade 1 to 2 and are generally controllable.

5. Necessity of genetic testing

Before using tepotinib, it must be confirmed whether the patient carries MET exon 14 skipping mutations through validated molecular detection methods such asNGS or PCR. Patients without such mutations usually do not benefit, so accurate diagnosis is a prerequisite to ensure efficacy.

6. Drug acquisition and accessibility

Tepotinib is currently on the market in China and has been included in my country's medical insurance system. Please consult your local hospital pharmacy for specific medical insurance reimbursement policies. The price of tepotinib purchased directly by patients in China may be relatively high, and the original drug is about more than 30,000 yuan. The cheaper ones on the foreign market are mainly Laotian generic drugs. Recently, the price of Tepotinib generic drugs produced by Lao Lucius and Lao Daxiong companies has been significantly reduced. The price is around more than 6,000 yuan, and the ingredients are basically the same as the domestic original drugs. .

Summary

Tepotinib, as a new generationMET inhibitor, has shown good efficacy and tolerability in the treatment of advanced NSCLC carrying METex14 skipping mutations, and is an important breakthrough in the field of precision therapy. With the popularization of genetic testing technology and the improvement of drug accessibility, its role in personalized treatment of lung cancer is expected to continue to rise in the future.

Reference materials:https://www.tepotinib.com/